welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Capricor Therapeutics announced today that it will meet with the U.S. Food and Drug Administration (FDA) in December to discuss clinical trial design, surrogate or intermediate endpoints and manufacturing processes for CAP-1002, Capricor’s novel cell therapy. Currently, patients are being enrolled in the HOPE-2 clinical trial, which is investigating CAP-1002 as a therapy for the treatment of Duchenne muscular dystrophy.
The in-person meeting is part of the expedited review process afforded to Capricor for its CAP-1002 product candidate after being granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA in February 2018. The FDA grants the RMAT designation to regenerative medicine therapies intended to treat a serious condition and for which preliminary clinical evidence indicates a potential to address unmet medical needs for that condition.
rareRelated
-
Tamoxifen in Duchenne Muscular DystrophyA randomised, double blind, placebo cont...
-
Solid Biosciences announces FDA removes clinical hold on SGT-001Solid Biosciences Inc. today announced t...
-
Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular DystrophyBackground: - Duchenne muscular dystrop...
-
Sarepta Therapeutics to Commence Dosing of the Next Study With Commercial Process Material for the SRP-9001 Gene The...Sarepta Therapeutics, Inc., the leader i...
-
New lab technology could reveal treatments for muscle-wasting diseaseResearchers from Queen Mary University o...
-
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a f...
-
Antisense Therapeutics to commence muscular dystrophy trialsAntisense Therapeutics is planning to un...
